Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for constructing DC vaccine modified by Ad-NK4

A construction method and vaccine technology, applied in the field of vaccines, can solve the problem of low immune effect of myeloma

Pending Publication Date: 2020-10-16
阙文忠
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The present invention aims at the technical defects of the prior art, and provides a method for constructing an Ad-NK4 modified DC vaccine to solve the technical problem of low immune effect of conventional DC vaccines on myeloma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for constructing DC vaccine modified by Ad-NK4
  • Method for constructing DC vaccine modified by Ad-NK4
  • Method for constructing DC vaccine modified by Ad-NK4

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] Specific embodiments of the present invention will be described in detail below. In order to avoid too many unnecessary details, well-known structures or functions will not be described in detail in the following embodiments. Approximate language used in the following examples is for quantitative representations, indicating that certain variations in quantities are permissible without altering essential function. Unless defined otherwise, technical and scientific terms used in the following examples have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0031] 1. Construction and identification of DC vaccine loaded with MM cell lysate

[0032] A. Collect U266 cells, centrifuge at 1000rpm / min for 5min, resuspend in PBS, and count. Dispense into cryopreservation tubes, 1.5ml per tube. Freeze in liquid nitrogen for 1 min, and quickly thaw in a 37°C water bath, repeating 3 times. Centrifuge at 5000rpm / min for ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a method for constructing a DC vaccine modified by Ad-NK4. According to the technical scheme, firstly, a human multiple myeloma cell lysate is prepared, meanwhile, DC is separated from peripheral blood of a patient with multiple myeloma and transfected with Ad-NK4, and finally, the human multiple myeloma cell lysate is used to sensitize the DC transfected by Ad-NK4 so as toobtain the DC vaccine modified by the Ad-NK4. On the basis, the immune efficacy of the vaccine is investigated through in vivo and in vitro experiments. The results confirm that the DC vaccine constructed in the invention can significantly inhibit the proliferation of MM cells in vitro, and has the effect of inducing apoptosis, and has obvious changes in cell proliferation, cell cycle, apoptosis and the expression of Akt-mTOR related proteins; and in an in vivo experiment part, in an experimental group administered with the vaccine, the tumor volume is obviously smaller and the tumor is obviously inhibited, thus confirming the technical effects of the DC vaccine.

Description

technical field [0001] The invention relates to the technical field of vaccines, in particular to a method for constructing an Ad-NK4 modified DC vaccine. Background technique [0002] Dendritic cells are professional antigen-presenting cells with the most powerful functions in the body. They can efficiently absorb, process and present antigens. Immature DCs have strong migration ability, and mature DCs can effectively activate naive T cells. Central link in the initiation, regulation, and maintenance of immune responses. [0003] DC tumor vaccine is to sensitize DC cells with tumor cell DNA, RNA, tumor cell lysate, tumor antigen protein / polypeptide, etc., and use the powerful presentation function of DC to activate the T cell immune response in the patient, so as to play a role in the treatment of tumors . However, tumor immunosuppression (TME) greatly limits the development of DC tumor vaccines, and the immune efficacy of conventional DC vaccines is not ideal. [0004] ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P35/00C12N5/10
CPCA61K39/0011A61P35/00C07K14/54C12N5/0639A61K2039/5154A61K2039/5158A61K2039/585C12N2501/2304C12N2501/22C12N2506/11
Inventor 阙文忠于梦玲徐尚华刘慧丽杨琴琴
Owner 阙文忠
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com